Showing 991-1000 of 5603 results for "".
Nonsurgical Skin Tightening and Facelifts
https://reachmd.com/series/c-suite-chats/nonsurgical-skin-tightening-and-facelifts/54266/Kim Laudati, founder and president of SomaCell, discusses recent demand for minimally invasive, natural-looking treatments and how her company's nonsurgical skin tightening and facelifts help address that trend.Face Value with Modern Aesthetics: Dr. Lisa Espinoza Debunks Misinformation Surrounding HA fillers
https://reachmd.com/series/face-value/face-value-with-modern-aesthetics-dr-lisa-espinoza-debunks-misinformation-surrounding-ha-fillers/49192/Lisa Espinoza, MD, discusses the Naturally You with Injectable Hyaluronic Acid Fillers report—and how she will incorporate this data with patients interested in HA fillers.Advancing Biomarker Testing Strategies in Upper GI Cancers: From PD-L1 to FGFR2b
https://reachmd.com/programs/project-oncology/advancing-biomarker-testing-strategies-in-upper-gi-cancers-from-pd-l1-to-fgfr2b/35504/From MSI and PD-L1 to emerging players like FGFR2b, biomarker testing is reshaping the management of upper GI cancers. But integrating these targets into timely, personalized treatment planning remains a challenge. So to help us navigate this evolving landscape, Dr. Charles Turck speaks with Dr. RutExamining Care Collaborations for Patients with SMA
https://reachmd.com/programs/neurofrontiers/examining-care-collaborations-for-patients-with-sma/36618/Collaborative care plays an important role in treating patients is spinal muscular dystrophy (SMA). To learn more about this, Dr. Andrew N. Wilner is joined by Drs. Vanessa Battista and Nassim Rad to share their insights on team structures and collaborative care for SMA.The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
https://reachmd.com/programs/project-oncology/the-evolving-treatment-landscape-for-extrapulmonary-neuroendocrine-carcinomas/36456/Emerging research is reshaping treatment for extrapulmonary neuroendocrine carcinomas, emphasizing the role of morphology, site of origin, and molecular targets like DLL3. Join Dr. Namrata Vijayvergia, Associate Professor of Hematology and Oncology and the Section Chief of Gastrointestinal Medical OPediatric Sickle Cell Disease: Analyzing Trends in Medication Utilization
https://reachmd.com/programs/project-oncology/pediatric-sickle-cell-disease-analyzing-trends-in-medication-utilization/36515/Pediatric sickle cell disease treatment, particularly the use of hydroxyurea, NSAIDs, and opioids, has evolved in response to clinical guidelines and regulatory shifts, but gaps still remain in how children receive essential medications. Joining Dr. Charles Turck to discuss these national prescribinSeborrheic Dermatitis Approaches and Stopping Biologic Treatment for Atopic Dermatitis
https://reachmd.com/conferences/scale-2025/seborrheic-dermatitis-approaches-and-stopping-biologic-treatment-for-atopic-dermatitis/35896/Naiem T. Issa, MD, PhD, talks at Music City SCALE 2025 about how to approach seborrheic dermatitis, as well as what happens to atopic dermatitis patients after ending biologic treatments.Journal Club: Dupilumab and Risk of Malignancy
https://reachmd.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseRedefining the Vascular Risks of Pregnant Patients with Marfan Syndrome
https://reachmd.com/programs/medical-industry-feature/redefining-the-vascular-risks-of-pregnant-patients-with-marfan-syndrome/24448/Learn how Dr. Narula’s research has redefined US guidelines for vascular risks in pregnant patients with Marfan Syndrome.Expanding the Scope of Nursing in the ACA Era
https://reachmd.com/programs/conversations-on-health-care/expanding-scope-nursing-aca-era/8021/This week, hosts Mark Masselli and Margaret Flinter speak with Mary Jo Assi, PhD, Director of Nursing Practice and Work Environment at the American Nurses Association which represents the nation's 3.4 million nurses. They discuss the expanding scope of the nursing work force in the ACA era, as well